<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2954-3835</journal-id>
<journal-title><![CDATA[Cardiovascular and metabolic science]]></journal-title>
<abbrev-journal-title><![CDATA[Cardiovasc. metab. sci]]></abbrev-journal-title>
<issn>2954-3835</issn>
<publisher>
<publisher-name><![CDATA[Asociación Nacional de Cardiólogos de México A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2954-38352021000200066</article-id>
<article-id pub-id-type="doi">10.35366/99743</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Efficacy of treatment with evolocumab in patients with ischemic heart disease]]></article-title>
<article-title xml:lang="es"><![CDATA[Eficacia del tratamiento con evolocumab en pacientes con cardiopatía isquémica]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramos-Martínez]]></surname>
<given-names><![CDATA[Juan Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández-Mercado]]></surname>
<given-names><![CDATA[Marco Antonio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez-Campos Mayoral]]></surname>
<given-names><![CDATA[Laura]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramos-Martínez]]></surname>
<given-names><![CDATA[Edgar Gustavo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto de Seguridad Social del Estado de México y Municipios Servicio de Cardiología y Cirugía Cardiovascular ]]></institution>
<addr-line><![CDATA[ Estado de México]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Autónoma Benito Juárez de Oaxaca Facultad de Medicina ]]></institution>
<addr-line><![CDATA[Oaxaca ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2021</year>
</pub-date>
<volume>32</volume>
<numero>2</numero>
<fpage>66</fpage>
<lpage>71</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2954-38352021000200066&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2954-38352021000200066&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2954-38352021000200066&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction:  A new target level for low-density lipoprotein cholesterol (LDL-C) has been established in patients at very high cardiovascular risk. However, treatment with evolocumab combined with atorvastatin to attain this target level has not been evaluated.  Objective:  To evaluate the efficacy of evolocumab to achieve the target LDL-C levels in patients with ischemic heart disease at very high cardiovascular risk.  Material and methods:  Twenty patients with ischemic heart disease at very high cardiovascular risk were treated with evolocumab and atorvastatin for 24 weeks. Levels of serum LDL-C, high-density lipoprotein cholesterol (HDL-C), total cholesterol, and triglycerides were determined before and after treatment.  Results:  After 24 weeks of treatment, an average percentage reduction of 55% for LDL-C was obtained, and 11 of the 20 patients reached the target levels for LDL-C. No differences were found in the levels of HDL-C or triglycerides.  Conclusions:  evolocumab treatment was safe, effective, and reduced the concentration of LDL-C in all patients. However, the target level for LDL-C was only reached in half of the patients.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  Se ha establecido un nuevo nivel objetivo de lipoproteína de baja densidad (C-LDL) en pacientes con muy alto riesgo cardiovascular. Sin embargo, no se ha evaluado si el tratamiento con evolocumab en combinación con atorvastatina permite alcanzar estos niveles.  Objetivo:  Evaluar la eficacia de evolocumab para lograr los niveles objetivo de C-LDL en pacientes con cardiopatía isquémica y muy alto riesgo cardiovascular.  Material y métodos:  Veinte pacientes con cardiopatía isquémica y muy alto riesgo cardiovascular fueron tratados con evolocumab más atorvastatina durante 24 semanas. Se determinaron los niveles de C-LDL, C-HDL, colesterol total y triglicéridos en suero antes y después del tratamiento.  Resultados:  Después de las 24 semanas de tratamiento, se obtuvo un promedio del porcentaje de reducción de C-LDL de 55% y 11 de los 20 pacientes alcanzaron los niveles objetivos de C-LDL. No se encontraron diferencias en los niveles de (lipoproteínas de alta densidad) HDL ni de triglicéridos.  Conclusiones:  El tratamiento con evolocumab fue seguro y eficaz, ya que redujo la concentración de C-LDL en todos los pacientes; sin embargo, sólo se alcanzó el nivel objetivo de C-LDL en la mitad de los pacientes.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Low density lipoprotein]]></kwd>
<kwd lng="en"><![CDATA[PCSK9 inhibitor]]></kwd>
<kwd lng="en"><![CDATA[evolocumab]]></kwd>
<kwd lng="en"><![CDATA[ischemic heart disease]]></kwd>
<kwd lng="en"><![CDATA[cholesterol]]></kwd>
<kwd lng="es"><![CDATA[Lipoproteína de baja densidad]]></kwd>
<kwd lng="es"><![CDATA[inhibidor PCSK9]]></kwd>
<kwd lng="es"><![CDATA[evolocumab]]></kwd>
<kwd lng="es"><![CDATA[cardiopatía isquémica]]></kwd>
<kwd lng="es"><![CDATA[colesterol]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seidah]]></surname>
<given-names><![CDATA[NG]]></given-names>
</name>
<name>
<surname><![CDATA[Awan]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Chrétien]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mbikay]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PCSK9: a key modulator of cardiovascular health]]></article-title>
<source><![CDATA[Circ Res]]></source>
<year>2014</year>
<volume>114</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1022-36</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Catapano]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Pirillo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Norata]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New pharmacological approaches to target PCSK9]]></article-title>
<source><![CDATA[Curr Atheroscler Rep]]></source>
<year>2020</year>
<volume>22</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>24</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Deibe]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
<name>
<surname><![CDATA[Pardo]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[IP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Actualidad de los Inhibidores de la PCSK9. [PCSK9 Inhibitors Update]]]></article-title>
<source><![CDATA[Rev Clínica Med Fam]]></source>
<year>2019</year>
<volume>12</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>125-31</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sabatine]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Giugliano]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Keech]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Honarpour]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Wiviott]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evolocumab and clinical outcomes in patients with cardiovascular disease]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2017</year>
<volume>376</volume>
<page-range>1713-22</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Robinson]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Nedergaard]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Rogers]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Fialkow]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Neutel]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Ramstad]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2014</year>
<volume>311</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>1870-82</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kiyosue]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Honarpour]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kurtz]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Xue]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Wasserman]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Hirayama]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A phase 3 study of evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2016</year>
<volume>117</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>40-7</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blom]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hala]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Bolognese]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lillestol]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Toth]]></surname>
<given-names><![CDATA[PD]]></given-names>
</name>
<name>
<surname><![CDATA[Burgess]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A 52-week placebo-controlled trial of evolocumab in hyperlipidemia]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2014</year>
<volume>370</volume>
<page-range>1809-19</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stroes]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Robinson]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Raal]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Dufour]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sullivan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kassahun]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies]]></article-title>
<source><![CDATA[Clin Cardiol]]></source>
<year>2018</year>
<volume>41</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1328-35</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mach]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Baigent]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Catapano]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Koskinas]]></surname>
<given-names><![CDATA[KC]]></given-names>
</name>
<name>
<surname><![CDATA[Casula]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Badimon]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2020</year>
<volume>41</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>111-88</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Catapano]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Backer G De, Wiklund]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Drexel]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guías ESC/EAS 2016 sobre el tratamiento de las dislipidemias. [ESC/EAS 2016 guide on the treatment of dyslipemias]]]></article-title>
<source><![CDATA[Rev Española Cardiol]]></source>
<year>2017</year>
<volume>70</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>115.e1-115.e64</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[de Labry Lima]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ballester]]></surname>
<given-names><![CDATA[VG]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[JFS]]></given-names>
</name>
<name>
<surname><![CDATA[Hoces]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[González-Outón]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[del Rey]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Coste-efectividad e impacto presupuestario del tratamiento con evolocumab frente a estatinas y ezetimiba para la hipercolesterolemia en España. [Cost-effectiveness and budgetary impact of treatment with evolocumab versus statins and ezetimibe for hypercholesterolemia in Spain]]]></article-title>
<source><![CDATA[Rev Española Cardiol]]></source>
<year>2018</year>
<volume>71</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1027-35</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grundy]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Stone]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bailey]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Beam]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Birtcher]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Blumenthal]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2018 Guideline on the management of blood cholesterol]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2019</year>
<volume>73</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>e285-350</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Black]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Espino]]></surname>
<given-names><![CDATA[DV]]></given-names>
</name>
<name>
<surname><![CDATA[Mahurin]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lichtenstein]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hazuda]]></surname>
<given-names><![CDATA[HP]]></given-names>
</name>
<name>
<surname><![CDATA[Fabrizio]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The influence of noncognitive factors on the Mini-Mental State Examination in older Mexican-Americans: findings from the Hispanic EPESE. Established Population for the Epidemiologic Study of the Elderly]]></article-title>
<source><![CDATA[J Clin Epidemiol]]></source>
<year>1999</year>
<volume>52</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1095-102</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Llamas-Velasco]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Llorente-Ayuso]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Contador]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Bermejo-Pareja]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Versiones en español del Minimental State Examination (MMSE). Cuestiones para su uso en la práctica clínica. [Spanish versions of the Mini-Mental State Examination (MMSE). Questions for use in clinical practice]]]></article-title>
<source><![CDATA[Rev Neurol]]></source>
<year>2015</year>
<volume>61</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>363-71</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Robinson]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Nedergaard]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Rogers]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Fialkow]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Neutel]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Ramstad]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2014</year>
<volume>311</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>1870-82</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tsuyuki]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
<name>
<surname><![CDATA[Bungard]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Poor adherence with hypolipidemic drugs: a lost opportunity]]></article-title>
<source><![CDATA[Pharmacotherapy]]></source>
<year>2001</year>
<volume>21</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>576-82</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Koren]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lundqvist]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bolognese]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Neutel]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Monsalvo]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2014</year>
<volume>63</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>2531-40</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giugliano]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Mach]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Zavitz]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kurtz]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Im]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kanevsky]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cognitive function in a randomized trial of evolocumab]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2017</year>
<volume>377</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>633-43</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
